Ali Rezai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ali Rezai sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Ali Rezai: 4 sponsored US clinical trials, 2 recruiting.
Ali Rezai sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease 1, with 1 trials.
Upper-quartile sponsor footprint
Ali Rezai sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
LIFU for Treatment for Refractory Opioid Use Disorder
NCT06218706
Low-Intensity Focused Ultrasound (LIFU) Neuromodulation
NCT05997030
Low Intensity Focused Ultrasound for Binge Eating Disorder
NCT06485687
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
NCT05469009
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Ali Rezai pipeline
2 recruiting of 4 indexed (50% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Alzheimer Disease 1 (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ali Rezai: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Ali Rezai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Ali Rezai page
4 registered trials is a research-attention snapshot, not an endorsement of Ali Rezai or any single study.
- 2 of Ali Rezai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alzheimer Disease 1 is the condition Ali Rezai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease 1 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ali Rezai pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.